Dual-target blockade: Simultaneously targets TL1A and α4β7, ensuring comprehensive inflammation control

Synergistic anti-inflammatory effect: Combined inhibition of TL1A-mediated pro-inflammatory signaling and α4β7-mediated lymphocyte migration significantly reduces inflammatory response

Extended half-life: Optimized pharmacokinetics enable reduced dosing frequency

High safety profile: Advanced design prevents immune complex formation and minimizes immunogenicity risk

Excellent druggability: High expression yield and stable formulation ensure clinical viability

Convenient Sc. administration: Enhances patient compliance with easy-to-use subcutaneous injection

TL1A inhibition: Blocks TL1A/DR3 signaling, reducing the release of pro-inflammatory cytokines such as IFNγ

α4β7 blockade: Prevents lymphocyte migration to the gut, reducing local immune cell infiltration

Combined action: The synergistic effect offers broad and effective inflammation modulation

IBD – Crohn’s Disease, Ulcerative Colitis

Route: Subcutaneous injection

Half-life: Extended (approximately 2–3× longer than conventional antibodies)

Dosing: Reduced frequency due to prolonged half-life